BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data  Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after updated Phase I/II data showed no new responses among 12 additional...
BC Extra | Jan 8, 2020
Company News

Pralsetinib data puts Blueprint on track for two FDA decisions this year

Blueprint moved a step closer to having two precision cancer therapies approved this year after announcing it started a rolling submission of an NDA for RET inhibitor pralsetinib along with updated Phase I/II data. Blueprint...
BC Extra | Sep 9, 2019
Clinical News

Loxo buy a step closer to paying off as Lilly heads to FDA with RET inhibitor

Lilly could have the best-in-class and first-in-class RET fusion inhibitor as it heads to FDA this year with the lead asset in its $8 billion acquisition of Loxo Oncology Inc. Eli Lilly and Co. (NYSE:LLY)...
BioCentury | Jun 28, 2019
Product Development

Why tissue-agnostic drug development needs NGS to go mainstream

Next-generation sequencing is emerging as the rate-limiting factor for how fast and broadly tissue-agnostic drug development will take off in drug development. By engaging community oncologists, some companies hope to spread the word and enable...
BC Extra | Jun 3, 2019
Clinical News

ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers

Updated data for Blueprint's BLU-667 in RET-altered cancers presented Monday at the American Society of Clinical Oncology meeting in Chicago show that the compound could be competitive with fellow RET inhibitor LOXO-292 from Eli Lilly...
BC Extra | Mar 29, 2019
Financial News

Blueprint raises $300M in follow-on, speeds regulatory timelines

Days after revealing new timelines for its lead program, Blueprint raised $300 million in a follow-on priced late Thursday. Blueprint Medicines Corp. (NASDAQ:BPMC) sold 4.1 million shares at $74, a 7% discount to the company's...
BC Week In Review | Jan 11, 2019
Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) said on Jan. 7 it reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in...
BC Extra | Jan 7, 2019
Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) has reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in the wake of the...
BC Innovations | Oct 25, 2018
Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
BC Week In Review | Oct 11, 2018
Clinical News

Rival RET inhibitor data highlighted at thyroid meeting

Loxo Oncology Inc. (NASDAQ:LOXO) and Blueprint Medicines Corp. (NASDAQ:BPMC) each reported updated data at the American Thyroid Association meeting in Washington from clinical trials evaluating their respective ret proto-oncogene (RET) inhibitors to treat RET-altered cancers....
Items per page:
1 - 10 of 22